- Hong Kong is rising as a wealth management center, attracting capital flight from volatile regions and surpassing Switzerland in this regard.
- Beijing intensified curbs on cross-border financial activity, affecting how mainland clients access global markets via Hong Kong.
Harbour BioMed is utilizing the Hong Kong Stock Market via Stock Connect for investor access, achieving a market cap over HK$10 billion.
1 report, 1 independent
Updated Sep 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Harbour BioMed is utilizing the Hong Kong Stock Market via Stock Connect for investor access, achieving a market cap over HK$10 billion.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Beijing intensified curbs on cross-border financial activity, affecting how mainland clients access global markets via Hong Kong.Also in this story
- Beijing introduced new regulations tightening scrutiny on overseas investments, driven by intensifying technological competition.
- Reuters reports on a crackdown concerning cross-border investment in China.
- Access to IPO materials was restricted in China and Hong Kong, while Citigroup declined to comment on the issues.
- Payoneer and Stripe are expanding their services and strategic partnerships into the rapidly growing APAC markets, including China and Hong Kong.
The entities involved
-
mainland China
geopolitical area under the jurisdiction of the People's Republic of China, excluding Special Administrative Regions
Related events
- HKEX ranks second globally after Nasdaq, benefiting from Chinese companies and Stock Connect.
- CKI has investments spanning Mainland China, its principal place of business in Hong Kong, and its registered office in Bermuda.
- HK government pushes for greater financial market maturity and plans to align with China's 15th Five-Year Plan.
- BIOHK2026 in Hong Kong was commended for integrating with China's development plans and serving as an international biotech hub.
- Mainland China's public securities revenue has been reported as a key driver of the market.